专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08906856B2 Single component fibrin hemostat 有权
标题翻译：单组分纤维蛋白止血剂
公开(公告)号：US08906856B2
公开(公告)日：2014-12-09
申请号：US13731120
申请日：2012-12-31
申请人： George David Falus , Leonid Medved
发明人： George David Falus , Leonid Medved
IPC分类号： A61K38/36 , C07K14/745
CPC分类号： A61K38/36 , A61L15/32 , A61L24/106 , A61L2400/04 , C07K14/745
摘要： ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application.
摘要翻译： ClotGel是一种单组分止血剂，设计用作中度术中出血和创伤中的辅助或主要治疗。它可以局部应用于伤口或者在皮肤上以解剖学的方式或在外科手术中以无创的方式施用。其交联技术使用止血所需的单一组分（纤维蛋白II）产生粘合稳定的纤维蛋白凝块。该试剂是冻干的聚合纤维蛋白II和纤维蛋白II单体的混合物，其在与血液接触时被聚合和稳定。凝胶的附着性质以及血纤维蛋白凝块的快速形成确保在施用1分钟内形成强烈的稳定的纤维蛋白凝块。

2. 发明授权

US08367802B2 Method to produce fibrin monomer in acid media for use as tissue sealant 失效
标题翻译：在酸性介质中生产纤维蛋白单体以用作组织密封剂的方法
公开(公告)号：US08367802B2
公开(公告)日：2013-02-05
申请号：US12487057
申请日：2009-06-18
申请人： George David Falus , Leonid Medved
发明人： George David Falus , Leonid Medved
IPC分类号： A61K38/36 , A61K38/00
CPC分类号： C07K14/745
摘要： A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.
摘要翻译：设计用于不可压缩性出血的止血剂。可以通过腹部，胸部，四肢或其他严重创伤后的混合针和/或喷射方法进行止血，以促进止血，或者可用于腹腔镜手术或其他无法压缩的外科手术。其交联技术产生粘合剂三维聚合物网络或支架，其携带止血所需的纤维蛋白密封剂。当混合时，它产生泡沫，其遍及到达撕裂组织的体腔，以密封组织并促进凝血级联。纤维蛋白组分通过新型透析方法产生，其不向免疫系统提供凝血酶，并且可以在溶液中维持六周而没有显着的蛋白水解降解。

3. 发明申请

US20120289467A1 Compositions and Methods Utilizing Fibrin Beta Chain Fragments 有权
标题翻译：使用纤维蛋白β链片段的组合物和方法
公开(公告)号：US20120289467A1
公开(公告)日：2012-11-15
申请号：US12678122
申请日：2008-09-17
申请人： Leonid Medved , Li Zhang , Sergiy Yakovlev
发明人： Leonid Medved , Li Zhang , Sergiy Yakovlev
IPC分类号： C07K14/75 , A61P9/10 , A61K38/36
CPC分类号： C07K14/75
摘要： A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66)2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.
摘要翻译：包含式＆bgr的肽序列X1-X2的组合物，所述肽序列对应于纤维蛋白原的Bbeta链的纤维蛋白β链片段的氨基酸序列，其中X1表示肽序列的N-末端， X2表示肽序列的C末端，其中肽序列包括X1和X2之间的额外氨基酸，其中肽序列可以含有非天然存在的氨基酸残基，其中肽序列不是野生型型单体序列本身，并且其中所述肽序列不同于具有每条链的每个链限定于野生型氨基酸（15-65）的每个链（＆amp; 15-66）2二聚体，并且每个链进一步包括每个链的位置66处的非天然存在的Gly。用于治疗和药物组合的方法可以包括多肽试剂例如胸腺素β4。在这些方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。

4. 发明申请

US20150359857A1 Aerosolized fibrin hemostat 审中-公开
标题翻译：气溶胶纤维蛋白止血剂
公开(公告)号：US20150359857A1
公开(公告)日：2015-12-17
申请号：US14247005
申请日：2014-04-07
申请人： George David Falus , Leonid Medved
发明人： George David Falus , Leonid Medved
IPC分类号： A61K38/45 , A61M11/02 , A61K38/36
CPC分类号： A61K38/45 , A61K38/36 , A61L26/0042 , A61L26/0076 , A61L2400/04 , A61M11/02 , A61M2202/0468 , A61M2202/064 , C07K14/745 , C12Y203/02013 , A61K2300/00
摘要： ClotSpray is a sprayable fibrin-based hemostatic agent applied from an aerosol can. The agent is intended for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and treatment of burns. It can be applied topically to the wound from an aerosol can without need of preparation, unfreezing or interruption during the length of the surgical procedure. Its crosslinking technology generates an adhesive fibrin sealant required for hemostasis. The attachment properties of the gel as well as the instant formation of a fibrin gel ensures that a strong stable fibrin clot will control light to moderate bleeding from a wound.
摘要翻译： ClotSpray是一种可喷雾的基于纤维蛋白的止血剂，由气溶胶罐应用。该药物旨在用作中度术中出血和治疗烧伤的辅助或主要治疗。它可以从气溶胶罐局部应用于伤口，而无需在外科手术过程中制备，解冻或中断。其交联技术产生止血所需的粘合纤维蛋白密封剂。凝胶的附着性质以及纤维蛋白凝胶的即时形成确保了强烈的稳定的纤维蛋白凝块可以控制光线从伤口缓和出血。

5. 发明授权

US08741845B1 Lyophilized fibrin sealant for high volume hemorrhage 失效
标题翻译：冻干纤维蛋白密封剂用于大体积出血
公开(公告)号：US08741845B1
公开(公告)日：2014-06-03
申请号：US13731126
申请日：2012-12-31
申请人： George David Falus , Leonid Medved
发明人： George David Falus , Leonid Medved
IPC分类号： A61K38/36 , A61K9/70 , C07K14/745
CPC分类号： A61K9/7007 , C07K14/745
摘要： ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.
摘要翻译： ClotBlock是一种冻干纤维蛋白止血剂，设计用于中度到重度出血的辅助或初级治疗。它可以在剖腹手术中直接应用于伤口或作为非侵入性密封剂。其交联技术产生强大和安全的粘合纤维蛋白密封剂，用于大量止血。蛋糕的附着性以及纤维蛋白凝块的快速形成和稳定性确保根据伤口的等级在1至5分钟内形成强烈的稳定的纤维蛋白凝块。该药物安全，生物相容，可生物降解，可在室温下储存一年。

6. 发明授权

US08722623B2 Compositions and methods utilizing fibrin beta chain fragments 有权
标题翻译：使用纤维蛋白β链片段的组合物和方法
公开(公告)号：US08722623B2
公开(公告)日：2014-05-13
申请号：US12678122
申请日：2008-09-17
申请人： Leonid Medved , Li Zhang , Sergiy Yakovlev
发明人： Leonid Medved , Li Zhang , Sergiy Yakovlev
IPC分类号： A61K38/36 , A61P7/04 , C07K14/75 , C07K14/475
CPC分类号： C07K14/75
摘要： A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66)2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.
摘要翻译：包含式＆bgr的肽序列X1-X2的组合物，所述肽序列对应于纤维蛋白原的Bbeta链的纤维蛋白β链片段的氨基酸序列，其中X1表示肽序列的N-末端， X2表示肽序列的C末端，其中肽序列包括X1和X2之间的额外氨基酸，其中肽序列可以含有非天然存在的氨基酸残基，其中肽序列不是野生型型单体序列本身，并且其中所述肽序列不同于具有每条链的每个链限定于野生型氨基酸（15-65）的每个链（＆amp; 15-66）2二聚体，并且每个链进一步包括每个链的位置66处的非天然存在的Gly。用于治疗和药物组合的方法可以包括多肽试剂例如胸腺素β4。在这些方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。

7. 发明申请

US20140187492A1 Single Component Fibrin Hemostat 有权
标题翻译：单组分纤维蛋白血症
公开(公告)号：US20140187492A1
公开(公告)日：2014-07-03
申请号：US13731120
申请日：2012-12-31
申请人： George David Falus , Leonid Medved
发明人： George David Falus , Leonid Medved
IPC分类号： A61L24/10
CPC分类号： A61K38/36 , A61L15/32 , A61L24/106 , A61L2400/04 , C07K14/745
摘要： ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application.
摘要翻译： ClotGel是一种单组分止血剂，设计用作中度术中出血和创伤中的辅助或主要治疗。它可以局部应用于伤口或者在皮肤上以解剖学的方式或在外科手术中以无创的方式施用。其交联技术使用止血所需的单一组分（纤维蛋白II）产生粘合稳定的纤维蛋白凝块。该试剂是冻干的聚合纤维蛋白II和纤维蛋白II单体的混合物，其在与血液接触时被聚合和稳定。凝胶的附着性质以及血纤维蛋白凝块的快速形成确保在施用1分钟内形成强烈的稳定的纤维蛋白凝块。

8. 发明申请

US20100197893A1 METHOD TO PRODUCE FIBRIN MONOMER IN ACID MEDIA FOR USE AS TISSUE SEALANT 失效
标题翻译：生产用于组织密封剂的酸性介质中的纤维单体的方法
公开(公告)号：US20100197893A1
公开(公告)日：2010-08-05
申请号：US12487057
申请日：2009-06-18
申请人： George Falus , Leonid Medved
发明人： George Falus , Leonid Medved
IPC分类号： C07K14/745
CPC分类号： C07K14/745
摘要： ClotFoam is an hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue. The fibrin components are produced by a novel method which does not present thrombin to immune system and can be maintained in solution for six weeks without significant proteolytic degradation.
摘要翻译： ClotFoam是一种用于非压缩性出血的止血剂。腹部，胸部，四肢或其他严重创伤后可以通过混合针和/或喷射法在手术室外进行止血，以促进止血，或者可用于手术室腹腔镜手术或其他外科手术其中压缩是不可能或推荐的。其交联技术产生粘合剂三维聚合物网络或支架，其携带止血所需的纤维蛋白密封剂。当混合时，Clotfoam产生一种泡沫，其遍及到达撕裂组织的体腔中，以密封组织并促进凝血级联。泡沫的粘弹性附着性以及快速形成纤维蛋白凝块，确保密封剂保持在施用位置，而不会被血液冲走或被靶组织移动而移位。纤维蛋白组分通过不向凝血酶提供免疫系统的新方法产生，并且可以在溶液中维持六周而没有明显的蛋白水解降解。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式